Altered Auditory Feedback Devices for Speech Dysfluency (Stuttering)
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1188 alerts
Get alerted when Policy CCP.1188 changes without checking for updates manually.
Monitor payer policy activity
This policy addresses coverage for altered auditory feedback (anti-stuttering) devices used to treat speech dysfluency (stuttering) and informs AmeriHealth Caritas coverage determinations for such devices and related services.
No material clinical or coverage changes in this revision.
Coverage Determinations
Not medically necessary
Altered auditory feedback devices are considered investigational and not medically necessary based on current evidence.
Supported by systematic reviews and randomized trial evidence showing insufficient and low-quality data; studies report some immediate reductions in stuttering but are limited by small samples, short follow-up, uncontrolled designs, and unclear durability of effect.
No specific policy limitations or exclusions were identified during the development of this policy.
Altered auditory feedback devices (also called anti-stammering devices, e.g., SpeechEasy) are electronic devices that manipulate how a person hears their own voice with the intent of reducing stuttering. AmeriHealth Caritas considers these devices investigational and not medically necessary due to insufficient, low-quality, and inconsistent evidence demonstrating durable clinical benefit. Systematic reviews and randomized trial data report some immediate reductions in stuttering for some patients but are limited by small sample sizes, short follow-up, methodological limitations, and a lack of control groups in many studies, preventing reliable conclusions about long-term effectiveness.
Related Codes
Provider Guidance and Actions
Prior authorization expectation — investigational devices
Altered auditory feedback devices are considered investigational and not medically necessary; prior authorization requests for these devices are expected to be denied based on this policy.
Alternative covered therapies — behavioral and speech therapy
Behavioral therapy and speech therapy for neurogenic stuttering are recommended as covered alternative services; providers should consider these established therapies instead of altered auditory feedback devices.
- Behavioral therapy
- Speech therapy for neurogenic stuttering
Denial risk — investigational device requests
Requests for altered auditory feedback (anti-stuttering) devices are considered investigational/not clinically proven and therefore are not medically necessary; coverage is expected to be denied on that basis.
Definitions
Background and Context
Stuttering (speech dysfluency) comprises involuntary interruptions to the forward flow of speech such as repetitions, prolongations, and blocks. It can occur developmentally in children or be acquired, and it may affect communication, social participation, and quality of life. Assessment typically includes observation and testing to determine type and severity and to guide individualized treatment planning. Conventional, evidence-based management emphasizes behavioral and speech therapy approaches; electronic altered auditory feedback devices have been developed to modify auditory feedback (for example, delayed or frequency-shifted feedback) so the user hears an altered version of their voice, with the goal of reducing involuntary dysfluencies. Evidence gaps remain regarding effectiveness during conversational speech, real-world durability of benefit, and which patients (if any) are most likely to benefit.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.